Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...
'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Lawmakers split after ...
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden ...
Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.
Modern Engineering Marvels on MSNOpinion
AI’s self‑improvement crossroads: The 2030 AGI risk window
Toward the end of this decade, a choice may face the species that could reshape its interactions with intelligence itself and ...
Former Google CEO Eric Schmidt expressed astonishment at AI's rapid progress, particularly its ability to autonomously generate code, admitting his ow ...
One of the most significant insights from the study is that roboticists must engage both technically and physically with ...
Tech Xplore on MSN
Enabling small language models to solve complex reasoning tasks
As language models (LMs) improve at tasks like image generation, trivia questions, and simple math, you might think that ...
November's wave of FDA oncology approvals signals the industry's shift toward platform-based precision therapies over broad-spectrum approaches([1]) . The global anticancer drug market now values ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback